INTRODUCTION
Human immune bodies, obtained from the blood of individuals who have had measles, when injected parenterally in exposed susceptibles in sufficient quantities and at a suitable interval from the time of exposure, have long been recognized as useful in attenuating or in passively protecting against measles. In the process of fractionation of pooled human plasma, developed for the production of normal human serum albumin by Cohn, Oncley, Strong, Hughes and Armstrong (1), fractions became available in which a variety of antibodies, reacting with certain viruses and bacteria, were found by Enders to be concentrated many times (2) . It became obvious that such concentrated preparations of antibodies should be useful against those diseases for which the attenuating, protective, or curative value of human immune plasma or sera had been demonstrated. The present report presents: A. A study of the use of such globulin fractions of human plasma for attenuation or passive protection against measles in 891 individuals who, as far as could be determined, were exposed susceptibles. B . A study of the use of globulin fractions containing the largest proportion of im1These investigations were aided in part through the mune bodies (chiefly gamma globulin) in the treatment of 61 individuals during the early stages of measles.
A. PASSIVE IMMUNIZATION

Materials used for prophylaxis
Two globulin fractions were used in these studies, Fraction II + III in the early work and Fraction II for most of the period of investigation. In Fraction II + III, the first crude concentrate containing all the gamma globulins and considerable beta globulin (1), Enders found the theoretically expected 8 to 10-fold concentration of many antibodies present in normal pooled plasma (2) . In Fraction II, the gamma globulins and antibodies were further purified (1) , so that the titer of those antibodies which appeared in this fraction (2) was from 15 to 35 times as high as in the original plasma pool.
In view of the concentration of immune bodies reacting with viruses in Fraction II, it appeared that the value of this fraction in measles should receive the more intensive study. Thus, a few preliminary tests were made of the value in measles of Fraction II + III, while the bulk of the data collected concerns the studies of Fraction II. Clinical material A measles epidemic, occurring through the winter of 1942 to 1943 and the spring of 1943 in the Philadelphia area, afforded the opportunity for a study of the value of the globulin fractions. Also, in the spring of 1943 in the Baltimore area, a measles epidemic appeared which gained little headway during the summer. However, in both areas, the disease was of considerably greater than average severity, -an opinion based first upon the relatively high incidence of cases of measles encephalitis; second upon the ease and severity with which monkeys contracted the disease when injected with blood from acute cases (3); and third, upon the high fever, extent of the rash, and other clinical signs and symptoms present. Most of the children studied resided in the Philadelphia area, while a smaller group was included from Baltimore. In the latter area, the results were obtained by one CzbeChaRpple amount of globulin used, is included in Table II. ;hur Peacock, In this summary, the lack of knowledge at first Rubin.
of the excellent protective value of the globulin The first was a pre-school group from 1 to 5 years, inclusive, which was considered as 100 per cent susceptible. The age range of the second group was 6 to 12 years, inclusive. These children also were suceptibles as far as could be determined, although the history of absence of measles at this age-range is somewhat less reliable. In Figure 1 are indicated the age ranges of the children within the two groups selected. Home exposures only were included and only children in whom the globulin had been injected within 7 days of exposure. The percentages of no measles in these two age groups of children are plotted against the amount of globulin injected to form the two curves shown in Figure 2 to lie in the difference in susceptibility of individual children. This difference appears to be clearly indicated when a large family of susceptibles, similarly exposed, suffer measles of varying severity. In such a consideration, it is assumed that the virus strain in a single epidemic remains the same. Despite the inability to determine for each child the size of dose which will protect or attenuate within the dosage range shown in Figure  2 , nevertheless when doses are selected either to the left or right of the curves indicated, i.e., below 0.25 cc. or above 4 to 5 cc., the parents can be given considerable assurance as to whether or not measles will occur in their exposed susceptibles. The same criteria obviously also apply to adult susceptibles. In general, therefore, the amounts necessary for protection and for attenuation may be outlined as follows: Again it must be emphasized that these are approximate figures, due to the difference in susceptibility of individuals.
In any attempt to outline the dosage per pound of body weight, a greater number of cases must be collected. Approximate estimations of proper dosage per pound of body weight, at all ages up to 12 years, are as follows: For attenuation, 0.02 cc. per pound; for protection, 0.08 cc. per pound. It is interesting that these results are in close agreement with those of Ordman, Jennings, and Janeway, as recorded in the following paper in this series (4) .
The advantages of the gamma globulin fraction of plasma, used in these studies, above other preparations of human immune bodies lie primarily in the small size of the dose required, the absence of materials other than those present in plasma, the absence of discomfort or reaction at the site of injection, and the absence of any generalized reaction. When In a few samples of Fraction II, "burning" at the site of injection was noted. This infrequent reaction appeared to depend, at least in part, upon a low pH, 6.1 to 6.2, of certain early preparations. The pH has now been standardized at pH 6.8 4 0. In summer, individuals appear to be less susceptible, although no conclusive data are available concerning this question. (5) The desire for complete protection or for attenuation. The general health of the child, the presence of other infectious diseases in the household or the community, the requirements of the social environment, activities, travel, convenience, etc., are all important considerations. (6) The potency of the prophylactic agent used, particularly as related to improper handling by the physician or distributor. When such variables are given full consideration by the physician, the proper dose of globulin Fraction II for the individual case may be obtained from such observations as are recorded in Figure 2 and Table III. In any final decision, the variable chances of complete protection or attenuation should be explained to the parents or the patient over the range of dosage thus indicated.
Summary
The serum gamma globulin, separated and concentrated by chemical fractionation of normal human blood, has been used in studies on measles prophylaxis. Two fractions, II + III, and Frac- 
Introduction
The use of large amounts of convalescent measles serum in the treatment of measles during its early stages has been studied by Levinson (5) . The generally favorable results obtained by these workers have been confirmed by a few unpublished records from the Philadelphia Serum Exchange of the Children's Hospital of Philadelphia and from other workers. Clearly demonstrable attenuation of the disease in such studies has occurred only when the convalescent serum has been injected in large amounts intravenously at the time of appearance of Koplik spots and before the appearance of any rash.
The demonstration of a high concentration of immune bodies against measles in the gamma globulin Fraction II of pooled human plasma; as indicated previously in this report, suggested the possible value of large amounts of this fraction injected intramuscularly 4 for the treatment of measles in its early stages. Part B of the present report records the results of such studies.
Material used for treatment
Fraction It + III was used for 8 children early in this study, while Fraction II, in view of its high titer of antiinfluenza A antibody and its demonstrated value for protection against or attenuation of measles, as outlined in Part A, was later selected for 53 children. The amount of gamma globulin available was somewhat limited during the major part of the studies on prophylaxis and until a valuable body of data was obtained in the studies of Part A, it did not appear justifiable to use large quantities of Fraction II in studies on treatment.
Clinical Matkrial
Sixty-one individuals are included in this report. The age range of this group is shown in Table IV . Those selected were as far as possible young children in whom a specified amount of globulin, when considered in relation to the size and weight of the individual, would be relatively more effective. The range of dosage used is also shown in Tables V and VI. The wide variation of dosage is due to lack of accurate knowledge concerning the antibody content of the globulin and the individual choices of physicians who attempted to judge the size of the dose given for treatment by their developing experience with Fraction II in prophylaxis. The difficulties of obtaining a large group of individuals in the home for treatment of measles before the rash has appeared or even during the earliest phases of the rash are far greater than may at first be supposed. The great majority of parents hesitate to call a physician during the earliest stages of any disease. This is particularly true of early measles, with its resemblance to the common cold, for which parents usually delay in calling a physician. In most children, the rash of measles appears before the decision is made.
Results
The individuals treated with the gamma globulin are best divided into two groups, according to presence or absence of rash at the time of injection. The rash by no means appears in a specified number of days from the beginning of the disease, but the sequence of events is fairly be included. For a group of this size, judgment as to the value of the globulin in treatment can be more exact than for its value in prophylaxis, because definite alterations in the course and severity of a disease can be noted and even in the early stages of measles some concept of its subsequent severity usually may be obtained. This is well shown by Figure 5 in which the columns appear almost as mirror images. On the other hand, in a study of prophylaxis, alterations in severity can be judged only by the accumulation of a sufficient number of cases for statistical comparison with other large groups. Where feasible, control cases without treatment, occurring at approximately the same time and in the same place, were included, although little importance is attached to obtaining an individual control for each case. As indicated in Part A, greater significance should be attached to over-all severity of the epidemic of which the children are a part than to the severity of the disease in individual controls. The wide variation in susceptibility of different children has been indicated in the curves shown in Figure 2 , Part A. Also, it is again worth noting that large families of exposed susceptibilities who have received no human immune bodies will vary greatly in the severity of measles among the individual children. The intimacy of exposure of individual children may be partially responsible for such variations as well as differing susceptibilities, but with such variations in severity of measles, the problem of selecting individual controls remains a difficult one. However, Table IV indicates the comparative severity of the disease in a group of treated children and a group of controls who received no globulin. The controls were either from the same family or had had exposures similar to those of the treated children.
The difference is striking between those 31 individuals treated before the rash appeared, i.e., during the stage of Koplik spots, and 30 treated immediately after the rash appeared. The better results obtained by the earlier use of the globulin are the more striking in consideration of the fact that two children are included in the former group who at no time developed a measles rash, despite a typical onset with many Koplik spots. In both of these children, the fever and other signs and symptoms subsided by crisis. Their occurrence earlier in the course of the study gave greater hope for such therapy in the dosages used than has appeared justified by later findings, however significant these may be. Though only two in number, the result is sufficiently unusual to warrant the conclusion that under the conditions obtaining in these cases, the therapeutic Of 30 individuals injected after the rash had started, there appeared to be modification of the disease in 13.
Of 31 individuals injected when Koplik spots were present but no rash, there appeared to be modification of the disease in 24. In 2 of these individuals, no rash developed.
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